EMSY stabilization in KEAP1-mutant lung cancer disrupts genome stability and type I interferon signaling.
作者信息
Sheban Daoud, Merbl Yifat
机构信息
Department of Systems Immunology, Weizmann Institute of Science, Rehovot, 7610001, Israel.
出版信息
Cell Death Differ. 2023 May;30(5):1397-1399. doi: 10.1038/s41418-023-01150-z. Epub 2023 Mar 23.
Abstract
摘要
相似文献
1
EMSY stabilization in KEAP1-mutant lung cancer disrupts genome stability and type I interferon signaling.KEAP1突变型肺癌中EMSY的稳定破坏了基因组稳定性和I型干扰素信号传导。
Cell Death Differ. 2023 May;30(5):1397-1399. doi: 10.1038/s41418-023-01150-z. Epub 2023 Mar 23.
2
EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion.EMSY 抑制同源重组修复和干扰素反应，促进肺癌的免疫逃逸。
Cell. 2022 Jan 6;185(1):169-183.e19. doi: 10.1016/j.cell.2021.12.005. Epub 2021 Dec 27.
3
KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis.KEAP1-NFE2L2突变型非小细胞肺癌与免疫检查点抑制剂：一项大型数据库分析
J Thorac Oncol. 2020 Jun;15(6):e85-e86. doi: 10.1016/j.jtho.2020.02.027.
4
Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.KEAP1-NFE2L2 通路突变定义了快速进展型肺腺癌的一个分子亚型。
J Thorac Oncol. 2019 Nov;14(11):1924-1934. doi: 10.1016/j.jtho.2019.07.003. Epub 2019 Jul 16.
5
KEAP1-NFE2L2 Mutations in NSCLC: Increased Awareness Needed. Reply to "KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis".非小细胞肺癌中KEAP1-NFE2L2突变：需要提高认识。对“KEAP1-NFE2L2突变型非小细胞肺癌与免疫检查点抑制剂：一项大型数据库分析”的回复
J Thorac Oncol. 2020 Jun;15(6):e87-e88. doi: 10.1016/j.jtho.2020.03.024.
6
Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.KEAP1/NRF2 突变型肺癌中分子亚型的临床病理、微环境和遗传决定因素。
Int J Cancer. 2019 Feb 15;144(4):788-801. doi: 10.1002/ijc.31975. Epub 2018 Dec 4.
7
PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC.PIDD 与 KEAP1 的相互作用作为一种新的突变非依赖性机制，促进 NSCLC 中 NRF2 的稳定和化学抗性。
Sci Rep. 2019 Aug 27;9(1):12437. doi: 10.1038/s41598-019-48763-4.
8
A Transcriptomic Approach Outperforms Mutational Analysis to Identify KEAP1/NFE2L2 Pathway Activation in Patients With NSCLC.一种转录组学方法在识别非小细胞肺癌患者KEAP1/NFE2L2通路激活方面优于突变分析。
J Thorac Oncol. 2023 Nov;18(11):1431-1433. doi: 10.1016/j.jtho.2023.08.002.
9
KEAP1 and TP53 Mutations in Lung Cancer: More Is Better. Reply to: "Survival Analysis of TP53 Co-Mutations Should Be Interpreted More Cautiously".肺癌中KEAP1和TP53突变：越多越好。对《TP53共突变的生存分析应更谨慎解读》的回复
J Thorac Oncol. 2022 Mar;17(3):e40-e41. doi: 10.1016/j.jtho.2021.12.001.
10
STK11 and KEAP1 Mutations in Lung Adenocarcinoma: Solving the Puzzle Continues.肺腺癌中STK11和KEAP1突变：解谜仍在继续。
J Thorac Oncol. 2022 Mar;17(3):351-352. doi: 10.1016/j.jtho.2022.01.004.
本文引用的文献
1
The BRCAness Landscape of Cancer.癌症的 BRCA 特征全景。
Cells. 2022 Dec 1;11(23):3877. doi: 10.3390/cells11233877.
2
EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion.EMSY 抑制同源重组修复和干扰素反应，促进肺癌的免疫逃逸。
Cell. 2022 Jan 6;185(1):169-183.e19. doi: 10.1016/j.cell.2021.12.005. Epub 2021 Dec 27.
3
and mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort.并在观察性真实世界肺腺癌队列中作为预后生物标志物的突变。
ESMO Open. 2020 Apr;5(2). doi: 10.1136/esmoopen-2020-000706.
4
The role of ubiquitination in tumorigenesis and targeted drug discovery.泛素化在肿瘤发生和靶向药物发现中的作用。
Signal Transduct Target Ther. 2020 Feb 29;5(1):11. doi: 10.1038/s41392-020-0107-0.
5
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.蛋白水解靶向嵌合体作为治疗方法和生物发现工具。
Cell. 2020 Apr 2;181(1):102-114. doi: 10.1016/j.cell.2019.11.031. Epub 2020 Jan 16.
6
STING: a master regulator in the cancer-immunity cycle.STING：癌症免疫周期中的主控调节器。
Mol Cancer. 2019 Nov 4;18(1):152. doi: 10.1186/s12943-019-1087-y.
7
Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.聚腺苷二磷酸核糖聚合酶（PARPs）作为治疗某些癌症的治疗靶点。
Expert Opin Ther Targets. 2019 Sep;23(9):773-785. doi: 10.1080/14728222.2019.1654458. Epub 2019 Aug 13.
8
Defining and Modulating 'BRCAness'.定义和调节“BRCA 样特征”。
Trends Cell Biol. 2019 Sep;29(9):740-751. doi: 10.1016/j.tcb.2019.06.005. Epub 2019 Jul 27.
9
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.泛肿瘤基因组生物标志物用于基于 PD-1 检查点阻断的免疫治疗。
Science. 2018 Oct 12;362(6411). doi: 10.1126/science.aar3593.
10
Nrf2-Keap1 signaling in oxidative and reductive stress.Nrf2-Keap1 信号通路在氧化和还原应激中的作用。
Biochim Biophys Acta Mol Cell Res. 2018 May;1865(5):721-733. doi: 10.1016/j.bbamcr.2018.02.010. Epub 2018 Feb 27.
Zotero 插件